Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471162 | 0.90 | ALDH1A1 (0.48) | SIGMAR1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL1775569 | 0.89 | GNAI3 (0.49) | ALDH1A1GNAI3GNAO1GNAI1ITGB3 | |
| Hydrochloric Acid SCHEMBL1930351 | 0.87 | GNAI3 (0.51) | ALDH1A1GNAI3GNAO1GNAI1ITGB3 | |
| Hydrochloric Acid SCHEMBL1931088 | 0.87 | GNAI3 (0.51) | ALDH1A1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL30734427 | 0.85 | ATM (0.48) | SIGMAR1ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL25504367 | 0.80 | GNAI3 (0.60) | SIGMAR1HTR1AHTR7GNAI3GNAO1 | |
| SCHEMBL14540476 | 0.80 | ATM (0.46) | ALDH1A1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL16756662 | 0.79 | GNAI3 (0.56) | GNAI3GNAO1GNAI1ITGB3ITGA2B | |
| SCHEMBL15065195 | 0.79 | CXCR4 (0.55) | SIGMAR1 | |
| SCHEMBL9415769 | 0.79 | GNAI3 (0.56) | GNAI3GNAO1GNAI1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | SIGMAR1 963/4885HTR1A 1653/4885HTR7 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.